Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

JUUL vs. cigarettes: which delivers nicotine faster?

NCT ID NCT04053868

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how nicotine enters the body when people use JUUL e-cigarettes compared to smoking regular tobacco cigarettes. Seventeen healthy adult smokers took part, and researchers measured nicotine levels and heart rate after each product. The goal was to understand the differences in nicotine delivery, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17 people

The number who actually took part.

Started

Dec 2019

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy on the basis of medical history and limited physical examination, as described below: * \- Heart rate \< 105 beats per minute (bpm) * \- - Considered out of range if both machine and manual readings are above/below these thresholds. * \- Systolic Blood Pressure \< 160 and \> 90\* * \- Diastolic Blood Pressure \< 100 and \> 50\* * Age: \>= 21 \& \<=70 years old * Body Mass Index (BMI) \<= 38.0 (at PI's discretion for higher BMI if no other concurrent health issues) * Willingness to avoid combusted marijuana up to 48 hours before each study visit * Nicotine strength of e-liquid of usual e-cigarette \> 0 mg/ml * Group 1 Experienced E-cigarette users * \- Current use of tobacco cigarettes (\<5 cigarettes per day) * \- Current e-cigarette use at least 15 days out of the past 30 days of a non-mod e-cigarette * Group 2 Primary Tobacco cigarette users: * \- Currently smoking \>= 5 cigarettes per day * \- Current e-cigarette use must be \< 5 times per month * Saliva cotinine \>=50 ng/ml or urine cotinine and/or NicAlert=6 * Must have a smart phone, computer, or tablet and internet access (for remote procedures) Exclusion Criteria: * Medical * \- Heart disease * \- Seizures * \- Cancer * \- Thyroid disease (okay if controlled with medication) * \- Diabetes * \- Hepatitis B or C or Liver disease * \- Glaucoma * \- Kidney disease or urinary retention * \- History of stroke * \- An ulcer in the past year * \- Active use of an inhaler for Asthma or Chronic Obstructive Pulmonary Disease (COPD) * Psychiatric conditions * \- Current or past schizophrenia, and/or current or past bipolar disorder * \- Major depression, current or within the past year * \- Major personality disorder * \- Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the principal investigator (PI) and/or medical monitor and considered for inclusion * \- History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's or medical monitor's approval * Drug/Alcohol Dependence * \- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program * \- Positive toxicology test for illicit drugs at the screening visit (Tetrahydrocannabinol (THC) \& prescribed medications okay) * \- Opioid replacement therapy (including methadone, buprenorphine, or other) * Psychiatric medications * \- Current regular use of any psychiatric medications is exclusionary, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRI) and current evaluation by the PI and/or medical monitor that the participant is otherwise healthy, stable, and able to participate * Medications * \- Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers) * \- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs) * \- Concurrent use of nicotine-containing medications * \- Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment * Use of Other Tobacco Products (OTP) * \- Any of the following products in combination more than 15 times in the past month * \- - smokeless tobacco (snus, oral snuff, chewing tobacco) * \- - pipes * \- - cigars, cigarillos, little cigars * \- - blunts, spliffs * \- - hookah * Other/Misc. Chronic Health Conditions * Fainting (within the last 30 days) * Other "life threatening illnesses" as per PI's or medical monitor's discretion * Pregnancy * \- Pregnancy (self-reported and urine pregnancy test) * \- Breastfeeding (determined by self-report) * Concurrent participation in another clinical trial (at PI's discretion) * Inability to read and write in English * Planning to quit smoking or vaping within the next 60 days * Recent onset or change (worsening) in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks * Diagnosis of pneumonia in the past 3 months * Uncomfortable with blood draws * Known allergy to propylene glycol or vegetable glycerin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for E-cigarettes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Tobacco Smoking Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • Zuckerberg San Francisco General Hospital

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.